Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Recruiting now · Phase 3

Conditions studied: Psoriatic Arthritis

In brief

Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time. Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 \[NCT06671483\] or TAK-279-PsA-3002 \[NCT06671496\]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD). Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.

Key facts

Study ID

NCT07286058

Run by

Takeda

People needed

1182

Starts

2026-03-11

Expected to finish

2029-12-18

Last updated by the study team

2026-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The participant is aged 18 years or older at the time of signing the informed consent form (ICF). In South Korea, the age requirement for adult participants is >=19 years of age.
• The participant has completed the 52-week treatment period in one of the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002) independent of treatment assignment, and without meeting the criteria for permanent discontinuation of trial intervention defined in the parent studies.
• The participant must be deemed by the investigator to benefit from continued or newly initiated (that is, for participants randomized to active comparator in parent study TAK-279-PsA-3001) zasocitinib therapy.

You may not qualify if…

• Any participant who is deemed by the investigator to be not benefiting from the trial intervention based upon lack of improvement or worsening of their symptoms in the respective parent study.
• Any participant who met the criteria for permanent discontinuation of trial intervention defined in the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002).
• The participant has developed any disease(s) that might confound the evaluations of benefit of zasocitinib therapy since enrollment in the respective parent study, including but not limited to rheumatoid arthritis, axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia.
• The participant has developed evidence of a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO).

Where it is running

• First OC Dermatology Research Inc. — Fountain Valley, California, United States (enrolling)
• Purushotham & Akther Kotha MD — La Mesa, California, United States (enrolling)
• Triwest Research Associates LLC — La Mesa, California, United States (enrolling)
• The Cohen Medical Centers — Thousand Oaks, California, United States (enrolling)
• Denver Arthritis Clinic - Lowry — Denver, Colorado, United States (enrolling)
• Direct Helpers Research Center — Hialeah, Florida, United States (enrolling)
• Sweet Hope Research Specialty, Inc, d/b/a Neoclinical Research — Hialeah, Florida, United States (enrolling)
• IRIS Research and Development — Plantation, Florida, United States (enrolling)
• Klein and Associates, M.D., P.A. — Hagerstown, Maryland, United States (enrolling)
• Paramount Medical Research & Consulting, LLC — Middleburg Heights, Ohio, United States (enrolling)
• West Tennessee Research Institute — Jackson, Tennessee, United States (enrolling)
• Accurate Clinical Research — Baytown, Texas, United States (enrolling)
• Novel Research LLC — Bellaire, Texas, United States (enrolling)
• Novel Research | Abigail Neiman - Houston, TX — Houston, Texas, United States (enrolling)
• Northwest Houston Arthritis Center — Houston, Texas, United States (enrolling)
• West Texas Clinical Research — Lubbock, Texas, United States (enrolling)
• Advanced Rheumatology of Houston — The Woodlands, Texas, United States (enrolling)
• R.K. Will Pty Ltd — Victoria Park, Western Australia, Australia (enrolling)
• Peking University Third Hospital — Beijing, Beijing Municipality, China (enrolling)
• Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (enrolling)
• Guangzhou First People's Hospital — Guangzhou, Guangdong, China (enrolling)
• Central South University - Xiangya School of Medicine - Zhuzhou Central Hospital — Zhuzhou, Hunan, China (enrolling)
• Linyi People's Hospital — Linyi Shi, Shandong, China (enrolling)
• First Hospital of Shanxi Medical University — Taiyuan, Shanxi, China (enrolling)
• MEDICAL Plus s.r.o. — Uherské Hradiště, Czechia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.